NasdaqGS:BIIBBiotechs
Is Biogen’s Recent Eisai Partnership a Turning Point for Its 2025 Stock Valuation?
Thinking about what to do with Biogen stock right now? You are not alone. There's a lot of debate swirling around this biotech giant, especially as its shares have been through quite the journey over the past few years. Some investors have been disappointed by the slide—down over 33.4% in the past year and more than 50% in the last five years—while others are starting to pay attention to signs that sentiment could be shifting.
Over the last week, Biogen stock crept up a modest 0.3%, with a...